Thromboangiitis obliterans (Buerger disease) drugs in development by stages, target, MoA, RoA, molecule type and key players, 2023

The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Thromboangiitis obliterans (Buerger disease) and features dormant and discontinued products.

GlobalData tracks six drugs in development for Thromboangiitis obliterans (Buerger disease) by six companies/universities/institutes. The top development phase for Thromboangiitis obliterans (Buerger disease) is preclinical with five drugs in that stage. The Thromboangiitis obliterans (Buerger disease) pipeline has five drugs in development by companies and one by universities/ institutes. Some of the companies in the Thromboangiitis obliterans (Buerger disease) pipeline products market are: AnGes, Biostar Stem Cell Research Institute and Antidote Therapeutics.

The key targets in the Thromboangiitis obliterans (Buerger disease) pipeline products market include Granulocyte Colony Stimulating Factor Receptor (CD114 or GCSFR or CSF3R), Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF), and E Selectin (CD62 Antigen Like Family Member E or Endothelial Leukocyte Adhesion Molecule 1 or Leukocyte Endothelial Cell Adhesion Molecule 2 or LECAM2 or CD62E or SELE).

The key mechanisms of action in the Thromboangiitis obliterans (Buerger disease) pipeline product include Granulocyte Colony Stimulating Factor Receptor (CD114 or GCSFR or CSF3R) Agonist with one drug in Preclinical. The Thromboangiitis obliterans (Buerger disease) pipeline products include six routes of administration with the top ROA being Intramuscular and five key molecule types in the Thromboangiitis obliterans (Buerger disease) pipeline products market including Gene Therapy, and Monoclonal Antibody.

Thromboangiitis obliterans (Buerger disease) overview

Thromboangiitis obliterans (TAO), also called Buerger disease, is a rare nonatherosclerotic inflammatory disorder in which blood vessels of the hands and feet become blocked. It has a strong association with smoking. Symptoms of Buerger’s disease are hand or foot pain (burning or tingling feeling), sores on toes or fingers, change in skin color or texture, and cold hands or feet. Diagnostic criteria of TAO include smoking history, onset before the age of 50 years, infra-popliteal arterial occlusions, either upper limb involvement or phlebitis migrans, and absence of atherosclerotic risk factors other than smoking. Treatment includes vasodilators like calcium channel blockers to improve blood flow, analgesics to help with pain and ulcer healing, anticoagulants to prevent blood clots, and antibiotics for ulcers. To prevent Buerger disease, patients are advised to stop tobacco use.

For a complete picture of Thromboangiitis obliterans (Buerger disease)’s pipeline drug market, buy the report here.

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.